SCHEMBL25937285

SCHEMBL25937285

CC(C)(C)OC(=O)NC1CC2(C1)CC(Oc1cccc(F)c1Br)C2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 4/20 0.39
EPHX2 P34913 1/20 0.38
KDM1A O60341 1/20 0.36
MAOB P27338 1/20 0.36
KMT2A Q03164 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
PARP1 P09874 2/20 0.35
ROCK2 O75116 3/20 0.34
KDM4D Q6B0I6 2/20 0.34
CACNB4 O00305 1/20 0.33
CACNA1A O00555 1/20 0.33
CACNA1G O43497 1/20 0.33
CACNG3 O60359 1/20 0.33
CACNA1F O60840 1/20 0.33
CACNA1H O95180 1/20 0.33
CACNB3 P54284 1/20 0.33
CACNA2D1 P54289 1/20 0.33
CACNG7 P62955 1/20 0.33
CACNA1B Q00975 1/20 0.33
CACNA1D Q01668 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25937244 0.88 CACNA1B (0.39) EPHX2KDM1AMAOBKMT2AL3MBTL1
SCHEMBL25937278 0.82 BTK (0.44) RORCEPHX2KDM1AMAOBKMT2A
SCHEMBL25937280 0.78 HCRTR1 (0.40) RORCEPHX2KDM1AMAOBKMT2A
SCHEMBL25937283 0.78 HCRTR1 (0.40) RORCEPHX2KDM1AMAOBKMT2A
SCHEMBL23889027 0.77 ROCK2 (0.42) PARP1ROCK2PDE4B
SCHEMBL29874413 0.75 SLC6A2 (0.45) RORCEPHX2KDM1AMAOBKMT2A
SCHEMBL9913822 0.74 KMT2A (0.42) RORCEPHX2KDM1AMAOBKMT2A
SCHEMBL24622410 0.73 GPR119 (0.36) RORCEPHX2KDM1AMAOBKMT2A
SCHEMBL24011177 0.73 EPHX2 (0.42) EPHX2KDM1AMAOBKMT2AL3MBTL1
SCHEMBL25938932 0.72 KDM1A (0.44) EPHX2KDM1AMAOBKMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230310423-A1 CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF BOUNDLESS BIO, INC. 2023-10-05 US disclosed
US-11707462-B2 Checkpoint kinase 1 (CHK1) inhibitors and uses thereof BOUNDLESS BIO, INC. (US) 2023-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230310423-A1 CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF CHEK1, CHEK2, RAD1 RORC 3231/4885EPHX2 3052/4885KDM1A 1547/4885
US-11707462-B2 Checkpoint kinase 1 (CHK1) inhibitors and uses thereof CHEK1, CHEK2, RAD1 RORC 3231/4885EPHX2 3052/4885KDM1A 1547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.